Trial Profile
An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naive Patients With Chronic Low Back Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Oxymorphone (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Endo Pharmaceuticals
- 06 Mar 2009 New trial record